Extracorporeal Photochemotherapy (ECP) has been recognised by the scientific community as a therapeutic option to treat various disorders, such as:

. Cutaneous T-cell lymphoma (Sezary syndrome) . GVHD (acute and chronic)
. Organ transplant rejection
. Autoimmune disorders
Macopharma has developed a complete product range for the off-line treatment of ECP: THERAFLEX – ECP.

 

Theraflex ECP Procedure

Extracorporeal photochemotherapy (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (8-methoxypsoralen or 8-MOP) and UVA illumination.
Mononuclear cells are harvested by cytapheresis and reinfused to the patient after cell illumination

 

REF. XUV8501Q – UVA ILLUMINATION EVA BAG XUV8501Q
Nominal volume: 3 L
Connections: 1 spike, 1 injection site
Download brochure for product description

 

 

REF. CSL1800XA – 8-MOP SOLUTION
Produit Thérapeutique Annexe (PTA)
Marketing Authorisation in France
AMM PTA N°: TA 07.10.109CSL1800XA
Volume: 5 mL
Chemical composition for 100 mL of solution:
Methoxalen………………………………………….2 mg
Ethanol (96%)………………………………..3230 mg
Glacial acetic acid……………………………..230 mg
Sodium acetate thrihydrate……………….860 mg
Sodium chloride…………………………………40 mg
Water for injections………………………….100 mL
Download brochure for product description

 

REF. 9MG200 – MACOGENIC G2 UVA ILLUMINATION DEVICE 
Weight: 65 kg
Dimensions: 87 cm (width) x 64 cm (depth) x 37 cm (height)
Download brochure for product description